Biossil

Every round on record, with the sources behind each and the investors on them.

A drug discovery company that acquires failed or shelved drug candidates and uses AI to identify new indications or development paths for them

Toronto, Ontario, CanadaBiotechFounded 2023

LATEST ROUND

Funding round

$43M · 2026-04-21

RAISED ON RECORD · USD

None

no verified round yet · plus 1 round still being checked

INVESTORS

2 leads

SOURCES

from 2 publishers

Rounds

[ 1 ]

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Funding round

$43M · 2026-04-21

[ HISTORY ]

led by Founders Fund, OpenAI

EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING

Financing · US$22-million · 2024

led by Founders Fund

Round	Amount	Announced	Lead	Buzz
Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$43M ~$70M to date	2026-04-21	Founders Fund, OpenAI	No recent discussion
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources Removed Golden Ventures · no source places them in this round Valuation exceeded US$100 million not stated for this round No source provides a dated announcement dateline, stage, valuation, headquarters, or additional round participants.

Company research

Fetched today

Biossil is a Toronto AI-native biopharma that acquires failed or shelved drug candidates and uses AI to identify new indications or development paths for them.

Founders

Anthony Mouchantaf · co-founder and CEO
He is a lawyer-turned-tech entrepreneur who previously headed Royal Bank of Canada's venture-capital investment strategy.
Alexander Mosa · co-founder, Chair and Chief Scientific Officer
He trained as an internal-medicine specialist, earned an MD and a PhD in virology, and trained at the University Health Network.

Business model

Biossil uses AI to identify promising failed or shelved drug candidates, buys or licenses them, advances them through clinical development, and earns cash and milestone-based revenue through licensing agreements with pharmaceutical and biotech companies.

WHY IT MATTERS

Biossil is targeting a costly drug-development failure mode: its AI reanalyzes late-stage candidates that may have failed because of patient selection, trial design, or the wrong endpoint, potentially reusing years of prior work instead of starting from scratch. The latest $153 million all-equity financing led by the OpenAI Startup Fund, at a reported $1 billion valuation, is intended to expand clinical-development capacity and acquire more candidates while Biossil advances programs including sickle-cell disease and glioblastoma.

Checked against 8 sources today

SOURCES

Sources

[ 2 ]

Funding round$43M2026-04-212 sources

Investors

[ 2 ]

Funding round$43M2026-04-212 investors

Founders Fund[ LEAD ]
OpenAI[ LEAD ]

Also named as backers in company research: OpenAI Startup Fund, Quiet Capital, Modern Capital, Golden Ventures, Panache Ventures, Staircase Ventures, 137 Ventures, DRI Healthcare, Duke University's endowment fund, Abu Dhabi Investment Council

EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING
Financing	US$22-million	2024	Founders Fund